Masimo Co. (NASDAQ:MASI) Receives $137.43 Consensus PT from Analysts

Masimo Co. (NASDAQ:MASI) has been assigned an average recommendation of “Hold” from the seven brokerages that are covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $137.43.

Several brokerages have recently issued reports on MASI. BTIG Research boosted their price objective on shares of Masimo from $145.00 to $166.00 and gave the company a “buy” rating in a research note on Monday, March 25th. Stifel Nicolaus upgraded Masimo from a “hold” rating to a “buy” rating and upped their price target for the stock from $148.00 to $170.00 in a research note on Monday, April 15th. Wells Fargo & Company upgraded Masimo from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $117.00 to $160.00 in a report on Monday, March 25th. Jefferies Financial Group reiterated a “hold” rating and set a $121.00 target price (up previously from $107.00) on shares of Masimo in a report on Tuesday, January 30th. Finally, Needham & Company LLC lowered shares of Masimo from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd.

Institutional Trading of Masimo

A number of hedge funds have recently made changes to their positions in MASI. State of Michigan Retirement System increased its position in shares of Masimo by 0.9% during the fourth quarter. State of Michigan Retirement System now owns 10,696 shares of the medical equipment provider’s stock worth $1,254,000 after acquiring an additional 100 shares during the last quarter. Massmutual Trust Co. FSB ADV grew its stake in Masimo by 140.6% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares in the last quarter. Parallel Advisors LLC increased its holdings in Masimo by 48.3% during the 4th quarter. Parallel Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $52,000 after purchasing an additional 145 shares during the last quarter. CWM LLC raised its position in shares of Masimo by 13.5% in the 4th quarter. CWM LLC now owns 1,318 shares of the medical equipment provider’s stock valued at $154,000 after purchasing an additional 157 shares in the last quarter. Finally, Riverview Trust Co purchased a new position in shares of Masimo during the 1st quarter valued at approximately $25,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Stock Performance

NASDAQ MASI opened at $136.14 on Friday. The business’s 50-day moving average price is $135.77 and its 200 day moving average price is $116.78. The company has a current ratio of 2.18, a quick ratio of 1.22 and a debt-to-equity ratio of 0.64. Masimo has a twelve month low of $75.22 and a twelve month high of $190.82. The company has a market capitalization of $7.20 billion, a PE ratio of 90.16 and a beta of 0.97.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.43. Masimo had a net margin of 3.98% and a return on equity of 13.77%. The company had revenue of $548.90 million during the quarter, compared to the consensus estimate of $545.69 million. During the same quarter in the prior year, the company posted $1.32 EPS. The company’s quarterly revenue was down 11.0% compared to the same quarter last year. On average, research analysts predict that Masimo will post 3.51 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.